Tech Company Financing Transactions
Passage Bio Funding Round
OrbiMed, Frazier Healthcare Partners and Lilly Asia Ventures participated in a $115.5 million Series A funding round for Passage Bio. The round was announced by the company on 2/19/2019.
Transaction Overview
Company Name
Announced On
2/19/2019
Transaction Type
Venture Equity
Amount
$115,500,000
Round
Series A
Investors
OrbiMed (Lead Investor) (Stephen Squinto)
Proceeds Purpose
The funding will be used to develop a portfolio of five therapeutic candidates to treat rare monogenic CNS diseases.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
2 Commerce Sq.
Philadelphia, PA 19103
USA
Philadelphia, PA 19103
USA
Phone
Website
Email Address
Not Recorded
Overview
Passage Bio was recently launched with the vision to be a first in class fully-integrated biotech company developing life transforming AAV-delivered in vivo therapeutics for the treatment of rare CNS diseases.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Stephen Squinto
Chief Operating Officer
Jill Quigley
Browse more venture capital transactions:
Prev: 2/19/2019: Smart Lunches venture capital transaction
Next: 2/19/2019: Avalanche Technology venture capital transaction
Share this article
Where The Data Comes From
We do our best to record every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The information is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs